IL6 and rheumatoid arthritis: There is abundant precedent for targeting IL-6 or its soluble receptor to ablate pathologic cytokine release cascades associated with rheumatoid arthritis (51), adoptive immunotherapy (52), or infectious disease and sepsis (53, 54).